General description
A hydroxamate-based inhibitor of matrix metalloproteinases and TACE (TNF-α convertase; ADAM17). Inhibits the activation-dependent shedding of L-selectin from neutrophils, eosinophils, and lymphocytes as well as phenylarsine oxide (PAO)-induced shedding in neutrophils. Also blocks the shedding of several cell surface proteins such as pro-TGF-α, IL-6 receptor α-subunit, and β-amyloid precursor protein. Reported to inhibit TNF-α release and impart protection against aspirin-induced gastric mucosal injury. Acts as a weak inhibitor of angiotensin converting enzyme (IC50 = 18 µM).
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Bennett, T.A., et al. 2000. J. Immunol.164, 4120.Fiorucci, S., et al. 1998. Aliment. Pharmacol. Ther.12, 1139.Hooper, N.M., et al. 1997. Biochem. J.321, 265.Parvathy, S., et al. 1997. Biochem. J.327, 37.Arribas, J., et al. 1996. J. Biol. Chem.271, 11376.
Packaging
Packaged under inert gas
1 mg in Glass bottle
Physical form
A 10 mM (1 mg/241 µL) sterile-filtered solution of TAPI-2 (Cat. No. 579052) in H2O.
Reconstitution
Following initial thaw, aliquot and freeze (-20°C). Aliquots are stable for up to 3 months at -20°C.
Warning
Toxicity: Standard Handling (A)
This product has met the following criteria to qualify for the following awards: